In the MIRACULUM phase II trial, which tested prolgolimab, a new anti-PD-1 monoclonal antibody, patients with advanced melanoma received either 1 mg/kg biweekly (Q2W) or 3 mg/kg every three weeks (Q3W). This evidence concerns the gene PDCD1 and melanoma.